D

Duopharma Biotech Bhd
KLSE:DPHARMA

Watchlist Manager
Duopharma Biotech Bhd
KLSE:DPHARMA
Watchlist
Price: 1.23 MYR Market Closed
Market Cap: 1.2B MYR
DPHARMA
/
Income Statement
/
Revenue

Duopharma Biotech Bhd
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Duopharma Biotech Bhd
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
D
Duopharma Biotech Bhd
KLSE:DPHARMA
Revenue
myr787.5m
CAGR 3-Years
8%
CAGR 5-Years
7%
CAGR 10-Years
16%
P
PeterLabs Holdings Bhd
KLSE:PLABS
Revenue
myr176m
CAGR 3-Years
-1%
CAGR 5-Years
13%
CAGR 10-Years
12%
A
Apex Healthcare Bhd
KLSE:AHEALTH
Revenue
myr961.8m
CAGR 3-Years
8%
CAGR 5-Years
7%
CAGR 10-Years
7%
R
Rhone Ma Holdings Bhd
KLSE:RHONEMA
Revenue
myr211.6m
CAGR 3-Years
8%
CAGR 5-Years
12%
CAGR 10-Years
N/A
Y
YSP Southeast Asia Holding Bhd
KLSE:YSPSAH
Revenue
myr368.7m
CAGR 3-Years
9%
CAGR 5-Years
5%
CAGR 10-Years
6%
K
Kotra Industries Bhd
KLSE:KOTRA
Revenue
myr235.7m
CAGR 3-Years
7%
CAGR 5-Years
7%
CAGR 10-Years
4%

Duopharma Biotech Bhd
Glance View

Market Cap
1.2B MYR
Industry
Pharmaceuticals

Duopharma Biotech Bhd.is an investment holding company, which engages in the manufacturing and distribution of pharmaceutical products. The company is headquartered in Klang, Selangor. The company went IPO on 2002-07-18. The Company, through its subsidiaries is engaged in manufacturing, distribution, importing and exporting of pharmaceutical products and medicines. The firm also engaged in research and development of pharmaceutical products. Its subsidiaries include Duopharma (M) Sendirian Berhad, Duopharma Manufacturing (Bangi) Sdn. Bhd., Duopharma Marketing Sdn. Bhd., Duopharma Consumer Healthcare Sdn. Bhd., Duopharma HAPI Sdn. Bhd., Duopharma Innovation Sdn. Bhd., Unique Pharmacy (Penang) Sdn. Bhd., Sentosa Pharmacy Sdn. Bhd., Duopharma Manufacturing (Glenmarie) Sdn. Bhd., Negeri Pharmacy Sdn. Bhd., Duopharma (Singapore) Pte. Ltd. and DB (Philippines), Inc.

DPHARMA Intrinsic Value
1.73 MYR
Undervaluation 29%
Intrinsic Value
Price
D
What is Intrinsic Value?

See Also

What is Duopharma Biotech Bhd's Revenue?
Revenue
787.5m MYR

Based on the financial report for Sep 30, 2024, Duopharma Biotech Bhd's Revenue amounts to 787.5m MYR.

What is Duopharma Biotech Bhd's Revenue growth rate?
Revenue CAGR 10Y
16%

Over the last year, the Revenue growth was 14%. The average annual Revenue growth rates for Duopharma Biotech Bhd have been 8% over the past three years , 7% over the past five years , and 16% over the past ten years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 241,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.